Hostname: page-component-76fb5796d-vfjqv Total loading time: 0 Render date: 2024-04-26T04:37:19.312Z Has data issue: false hasContentIssue false

First report of IMP-1 in a clinical isolate of Escherichia coli in Latin America

Published online by Cambridge University Press:  08 June 2020

Priscila Lamb Wink*
Affiliation:
LABRESIS–Laboratório de Pesquisa em Resistência Bacteriana, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
Evelyn Kern Almeida
Affiliation:
LABRESIS–Laboratório de Pesquisa em Resistência Bacteriana, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil
Marina Niada Crispim
Affiliation:
LABRESIS–Laboratório de Pesquisa em Resistência Bacteriana, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil
Daiana de Lima-Morales
Affiliation:
LABRESIS–Laboratório de Pesquisa em Resistência Bacteriana, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil
Alexandre P. Zavascki
Affiliation:
LABRESIS–Laboratório de Pesquisa em Resistência Bacteriana, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil Department of Internal Medicine, Medical School, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil Infectious Diseases Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
Afonso Luís Barth
Affiliation:
LABRESIS–Laboratório de Pesquisa em Resistência Bacteriana, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
*
Author for correspondence: Priscila Lamb Wink, E-mail: pris_farma@yahoo.com.br
Rights & Permissions [Opens in a new window]

Abstract

Type
Letter to the Editor
Copyright
© 2020 by The Society for Healthcare Epidemiology of America. All rights reserved.

To the Editor—The emergence of carbapenem-resistant Enterobacterales (CRE) is a matter of public health concern that seriously compromises antibiotic treatment for severe infections. Since the first report of acquired IMP-1 in Pseudomonas aeruginosa in Japan in 1988,Reference Watanabe, Iyobe, Inoue and Mitsuhashi1 genes encoding IMP enzymes have spread rapidly among Acinetobacter spp and Enterobacterales.Reference Zhao and Hu2 Here, we describe the characteristics of a clinical isolate of E. coli harboring bla IMP-1 gene in Latin America.

An Escherichia coli (termed E. coli 7469F) was recovered from the blood of a patient at Hospital de Clínicas de Porto Alegre in Southern Brazil in May 2019. The E. coli 7469F was not susceptible in vitro to meropenem and ertapenem by the disk-diffusion method. The presence of carbapenemase genes (bla NDM-1, bla KPC-2, bla VIM-type, bla GES-type, bla OXA-48-like, and bla IMP-type) was evaluated using multiplex high-resolution melting (HRM) real-time polymerase chain reaction (PCR),Reference Monteiro, Widen, Pignatari, Kubasek and Silbert3 which yielded a positive result only for the bla IMP-type gene. The clinical isolate was submitted to conjugation experiment using E. coli J53 as a receptor, and 1 transconjugant (T7469F) was selected for further analysis. The minimal inhibitory concentrations (MICs) of antibiotics representative of β-lactams, aminoglycosides, glycilcycline, and chloramphenicol were evaluated by broth microdilution for the E. coli 7469F and its transconjugant (T7469F). The transconjugant T7469F presented significant increase in MICs of the carbapenems and ceftazidime compared with E. coli J53 (Table 1). T7469F did not present an increased MIC for aminoglycosides, chloramphenicol, or tigecycline. This whole-genome shotgun project has been deposited at DDBJ/ENA/GenBank under the accession WTVT00000000. The version described here is version WTVT01000000.

Table 1. Minimal Inhibitory Concentrations (MICs) of Several Antibiotics Used to Treat Escherichia coli 7469F, Transconjugant 7469F, and E. coli J53

The whole genomes of the clinical isolate and its transconjugant were sequenced using the MiSeq platform (Illumina, San Diego, CA), and the data were analyzed using the following tools from the Centre for Genomic Epidemiology website (http://www.genomicepidemiology.org): MLST to characterize sequence typing (ST), ResFinder to characterize antibiotic resistance mechanisms, and PlasmidFinder to characterize plasmid types. Analyses of the whole-genome sequencing (WGS) data confirmed the presence of the bla IMP-1 gene in isolate 7469F and its transconjugant. Other genes related to resistance to β-lactam (bla CTX-M-15 and bla OXA-1) were found in the clinical isolate using in silico data analyses. E. coli 7469F presented 4 plasmids, and the bla IMP-1 gene was identified in the plasmid IncA/C2. In silico data confirmed that the IncA/C2 was the only plasmid identified in the transconjugant T7469F. Plasmids belonging to the IncA/C incompatibility group are broad host–range vehicles commonly identified among animal and clinical bacterial isolates of Enterobacterales worldwide. This plasmid usually harbors different resistance genes, including bla CMY, bla NDM, bla VIM, and bla IMP.Reference Harmer and Hall4 The WGS analyses also indicated that the E. coli 7469F belonged to the ST648. ST648 is a predominant multidrug-resistant ST observed worldwide; it is increasingly reported in multiple regions.Reference Ewers, Bethe and Stamm5-Reference Johnson, Johnston and Gordon8 In addition, several publications have reported the frequent occurrence of ST648 strains with various β-lactamases (extended-spectrum β-lactamases [ESBLs], New Delhi metallo-β-lactamases [NDMs], and Klebsiella pneumoniae carbapenemase [KPCs]),Reference Kim, Qureshi, Adams-Haduch, Park, Shutt and Doi9,Reference Mushtaq, Irfan and Sarma10 as well as the mcr-1 gene.Reference Johnson, Johnston and Gordon8

To the best of our knowledge, this is the first report of a clinical isolate of E. coli ST648 carrying an IncA/C2 plasmid with the bla IMP-1 gene in Latin America. Notably, the broad host range of IncA/C2 plasmid may contribute to the diffusion and maintenance of bla IMP-1 in different groups of bacteria. Considering the concerning spread of carbapenem resistance mediated by plasmids and considering the high prevalence of ST648 E. coli, our study highlights the importance of continuous surveillance studies of carbapenemase genes in Latin America.

Acknowledgments

The authors would like to thank Helena de Ávila Peixoto e Silva for technical support.

Financial support

This work was supported by Instituto Nacional de Pesquisa em Resistência Antimicrobiana Brazil (INCT/CNPq grant no. 465718/2014-0 and INCT/FAPERGS grant no: 17/2551-0000514-7) and by Fundo de Incentivo à Pesquisa e Eventos do Hospital de Clínicas de Porto Alegre (FIPE/HCPA grant no. 2018-0205). P.L.W. and D.L.M. were supported by a grant from the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES). E.K.A. was supported by a grant from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). M.N.C. was supported by a grant from Fundação de Amparo à Pesquisa do Rio Grande do Sul (FAPERGS). A.L.B. and A.P.Z. are a research fellow of the CNPq.

Conflicts of interest

All authors report no conflicts of interest relevant to this article.

References

Watanabe, M, Iyobe, S, Inoue, M, Mitsuhashi, S. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agent Chemother 1991;35:147–51.CrossRefGoogle ScholarPubMed
Zhao, WH, Hu, ZQ. IMP-type metallo-β-lactamases in gram-negative bacilli: distribution, phylogeny, and association with integrons. Crit Rev Microbiol 2011;37:214226.CrossRefGoogle ScholarPubMed
Monteiro, J, Widen, RH, Pignatari, AC, Kubasek, C, Silbert, S. Rapid detection of carbapenemase genes by multiplex real-time PCR. J Antimicrob Chemother 2012;67:906909.CrossRefGoogle ScholarPubMed
Harmer, CJ, Hall, RM. The A to Z of A/C plasmids. Plasmid 2015;80:6382.CrossRefGoogle Scholar
Ewers, C, Bethe, A, Stamm, I, et al.CTX-M-15-D-ST648 Escherichia coli from companion animals and horses: another pandemic clone combining multiresistance and extraintestinal virulence? J Antimicrob Chemother 2014;69:12241230.CrossRefGoogle ScholarPubMed
Peirano, G, van der Bij, AK, Gregson, D, Pitout, JD. Molecular epidemiology over an 11-year period (2000 to 2010) of extended spectrum β-lactamase–producing Escherichia coli causing bacteremia in a centralized Canadian region. J Clin Microbiol 2012;50:294299.CrossRefGoogle Scholar
Zong, Z, Yu, R. Escherichia coli carrying the blaCTX-M-15 gene of ST648. J Med Microbiol 2010;59:15361537.CrossRefGoogle ScholarPubMed
Johnson, JR, Johnston, BD, Gordon, DM. Rapid and specific detection of the Escherichia coli sequence type 648 complex within phylogroup F. J Clin Microbiol 2017;55:11161121.CrossRefGoogle ScholarPubMed
Kim, YA, Qureshi, ZA, Adams-Haduch, JM, Park, YS, Shutt, KA, Doi, Y. Features of infections due to Klebsiella pneumoniae carbapenemase producing Escherichia coli: emergence of sequence type 131. Clin Infect Dis 2012;55:224231.CrossRefGoogle ScholarPubMed
Mushtaq, S, Irfan, S, Sarma, JB, et al.Phylogenetic diversity of Escherichia coli strains producing NDM-type carbapenemases. J Antimicrob Chemother 2011;66:20022005.CrossRefGoogle ScholarPubMed
Figure 0

Table 1. Minimal Inhibitory Concentrations (MICs) of Several Antibiotics Used to Treat Escherichia coli 7469F, Transconjugant 7469F, and E. coli J53